274 related articles for article (PubMed ID: 31074033)
21. Predictive role of diffusion-weighted whole-body MRI (DW-MRI) imaging response according to MY-RADS criteria after autologous stem cell transplantation in patients with multiple myeloma and combined evaluation with MRD assessment by flow cytometry.
Belotti A; Ribolla R; Cancelli V; Villanacci A; Angelini V; Chiarini M; Giustini V; Facchetti GV; Roccaro AM; Ferrari S; Peli A; Bottelli C; Cattaneo C; Crippa C; Micilotta M; Frittoli B; Grazioli L; Rossi G; Tucci A
Cancer Med; 2021 Sep; 10(17):5859-5865. PubMed ID: 34263564
[TBL] [Abstract][Full Text] [Related]
22. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.
Paiva B; Vidriales MB; Cerveró J; Mateo G; Pérez JJ; Montalbán MA; Sureda A; Montejano L; Gutiérrez NC; García de Coca A; de Las Heras N; Mateos MV; López-Berges MC; García-Boyero R; Galende J; Hernández J; Palomera L; Carrera D; Martínez R; de la Rubia J; Martín A; Bladé J; Lahuerta JJ; Orfao A; San Miguel JF;
Blood; 2008 Nov; 112(10):4017-23. PubMed ID: 18669875
[TBL] [Abstract][Full Text] [Related]
23. Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?
Kothari S; Hillengass J; McCarthy PL; Holstein SA
Curr Hematol Malig Rep; 2019 Feb; 14(1):39-46. PubMed ID: 30671912
[TBL] [Abstract][Full Text] [Related]
24. Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
Martinez-Lopez J; Alonso R; Wong SW; Rios R; Shah N; Ruiz-Heredia Y; Sanchez-Pina JM; Sanchez R; Bahri N; Zamanillo I; Poza M; Buenache N; Encinas C; Juarez L; Miras F; Collado L; Barrio S; Martin T; Cedena MT; Wolf J
J Hematol Oncol; 2021 Aug; 14(1):126. PubMed ID: 34404440
[TBL] [Abstract][Full Text] [Related]
25. High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.
Bertamini L; Oliva S; Rota-Scalabrini D; Paris L; Morè S; Corradini P; Ledda A; Gentile M; De Sabbata G; Pietrantuono G; Pascarella A; Tosi P; Curci P; Gilestro M; Capra A; Galieni P; Pisani F; Annibali O; Monaco F; Liberati AM; Palmieri S; Luppi M; Zambello R; Fazio F; Belotti A; Tacchetti P; Musto P; Boccadoro M; Gay F
J Clin Oncol; 2022 Sep; 40(27):3120-3131. PubMed ID: 35666982
[TBL] [Abstract][Full Text] [Related]
26. The prognostic value of multiparameter flow cytometry minimal residual disease assessment in relapsed multiple myeloma.
Paiva B; Chandia M; Puig N; Vidriales MB; Perez JJ; Lopez-Corral L; Ocio EM; Garcia-Sanz R; Gutierrez NC; Jimenez-Ubieto A; Lahuerta JJ; Mateos MV; San Miguel JF
Haematologica; 2015 Feb; 100(2):e53-5. PubMed ID: 25381128
[No Abstract] [Full Text] [Related]
27. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
28. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.
Rasche L; Alapat D; Kumar M; Gershner G; McDonald J; Wardell CP; Samant R; Van Hemert R; Epstein J; Williams AF; Thanendrarajan S; Schinke C; Bauer M; Ashby C; Tytarenko RG; van Rhee F; Walker BA; Zangari M; Barlogie B; Davies FE; Morgan GJ; Weinhold N
Leukemia; 2019 Jul; 33(7):1713-1722. PubMed ID: 30573775
[TBL] [Abstract][Full Text] [Related]
29. Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial.
Zamagni E; Oliva S; Gay F; Capra A; Rota-Scalabrini D; D'Agostino M; Belotti A; Galli M; Racca M; Zambello R; Gamberi B; Albano D; Bertamini L; Versari A; Grasso M; Sgherza N; Priola C; Fioritoni F; Patriarca F; De Cicco G; Villanova T; Pascarella A; Zucchetta P; Tacchetti P; Fanti S; Mancuso K; Barbato S; Boccadoro M; Musto P; Cavo M; Nanni C
EClinicalMedicine; 2023 Jun; 60():102017. PubMed ID: 37396807
[TBL] [Abstract][Full Text] [Related]
30. Prospective Evaluation of Magnetic Resonance Imaging and [
Moreau P; Attal M; Caillot D; Macro M; Karlin L; Garderet L; Facon T; Benboubker L; Escoffre-Barbe M; Stoppa AM; Laribi K; Hulin C; Perrot A; Marit G; Eveillard JR; Caillon F; Bodet-Milin C; Pegourie B; Dorvaux V; Chaleteix C; Anderson K; Richardson P; Munshi NC; Avet-Loiseau H; Gaultier A; Nguyen JM; Dupas B; Frampas E; Kraeber-Bodere F
J Clin Oncol; 2017 Sep; 35(25):2911-2918. PubMed ID: 28686535
[TBL] [Abstract][Full Text] [Related]
31. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients.
Fonseca R; Arribas M; Wiedmeier-Nutor JE; Kusne YN; González Vélez M; Kosiorek HE; Butterfield RDJ; Kirsch IR; Mikhael JR; Stewart AK; Reeder C; Larsen J; Bergsagel PL; Fonseca R
Blood Cancer J; 2023 Mar; 13(1):32. PubMed ID: 36878906
[TBL] [Abstract][Full Text] [Related]
32. Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial.
Bodet-Milin C; Morvant C; Carlier T; Frecon G; Tournilhac O; Safar V; Kraeber-Bodere F; Le Gouill S; Macintyre E; Bailly C
Sci Rep; 2023 Oct; 13(1):18177. PubMed ID: 37875524
[TBL] [Abstract][Full Text] [Related]
33. Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT.
Lecouvet FE; Vekemans MC; Van Den Berghe T; Verstraete K; Kirchgesner T; Acid S; Malghem J; Wuts J; Hillengass J; Vandecaveye V; Jamar F; Gheysens O; Vande Berg BC
Skeletal Radiol; 2022 Jan; 51(1):59-80. PubMed ID: 34363522
[TBL] [Abstract][Full Text] [Related]
34. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.
Landgren O; Devlin S; Boulad M; Mailankody S
Bone Marrow Transplant; 2016 Dec; 51(12):1565-1568. PubMed ID: 27595280
[TBL] [Abstract][Full Text] [Related]
35. What to do with minimal residual disease testing in myeloma.
Manasanch EE
Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
[TBL] [Abstract][Full Text] [Related]
36. Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma.
Böckle D; Tabares P; Zhou X; Schimanski S; Steinhardt MJ; Bittrich M; Seebacher E; Ulbrich M; Wilnit A; Metz C; Heidemeier A; Bley T; Werner R; Buck A; Einsele H; Kortüm KM; Beilhack A; Rasche L
Br J Haematol; 2022 Aug; 198(3):515-522. PubMed ID: 35582835
[TBL] [Abstract][Full Text] [Related]
37. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction.
Rawstron AC; Gregory WM; de Tute RM; Davies FE; Bell SE; Drayson MT; Cook G; Jackson GH; Morgan GJ; Child JA; Owen RG
Blood; 2015 Mar; 125(12):1932-5. PubMed ID: 25645353
[TBL] [Abstract][Full Text] [Related]
38. Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.
Avet-Loiseau H; Ludwig H; Landgren O; Paiva B; Morris C; Yang H; Zhou K; Ro S; Mateos MV
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):e30-e37. PubMed ID: 31780415
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of [
Stolzenburg A; Lückerath K; Samnick S; Speer M; Kneer K; Schmid JS; Grigoleit GU; Hofmann S; Beer AJ; Bunjes D; Knop S; Buck AK; Einsele H; Lapa C
Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1694-1704. PubMed ID: 29610955
[TBL] [Abstract][Full Text] [Related]
40. Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).
Fan H; Wang B; Shi L; Pan N; Yan W; Xu J; Gong L; Li L; Liu Y; Du C; Cui J; Zhu G; Deng S; Sui W; Xu Y; Yi S; Hao M; Zou D; Chen X; Qiu L; An G
Clin Cancer Res; 2024 Mar; 30(6):1131-1142. PubMed ID: 38170583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
